company background image
524348 logo

Aarti Drugs BSE:524348 Stock Report

Last Price

₹441.10

Market Cap

₹40.6b

7D

0.6%

1Y

30.8%

Updated

27 Mar, 2024

Data

Company Financials +

524348 Stock Overview

Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

524348 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends2/6

Aarti Drugs Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aarti Drugs
Historical stock prices
Current Share Price₹441.10
52 Week High₹645.00
52 Week Low₹332.15
Beta0.90
1 Month Change-14.12%
3 Month Change-10.65%
1 Year Change30.81%
3 Year Change-36.51%
5 Year Change185.55%
Change since IPO14,603.33%

Recent News & Updates

Recent updates

Shareholder Returns

524348IN PharmaceuticalsIN Market
7D0.6%2.7%2.5%
1Y30.8%63.9%47.3%

Return vs Industry: 524348 underperformed the Indian Pharmaceuticals industry which returned 65% over the past year.

Return vs Market: 524348 underperformed the Indian Market which returned 48.6% over the past year.

Price Volatility

Is 524348's price volatile compared to industry and market?
524348 volatility
524348 Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: 524348 has not had significant price volatility in the past 3 months.

Volatility Over Time: 524348's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19841,003Prakash Patilhttps://www.aartidrugs.co.in

Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer’s treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides.

Aarti Drugs Limited Fundamentals Summary

How do Aarti Drugs's earnings and revenue compare to its market cap?
524348 fundamental statistics
Market cap₹40.55b
Earnings (TTM)₹1.80b
Revenue (TTM)₹26.51b

22.5x

P/E Ratio

1.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524348 income statement (TTM)
Revenue₹26.51b
Cost of Revenue₹18.18b
Gross Profit₹8.33b
Other Expenses₹6.53b
Earnings₹1.80b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)19.60
Gross Margin31.43%
Net Profit Margin6.80%
Debt/Equity Ratio48.7%

How did 524348 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

5%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.